A new method of intermittent lower dose of tolvaptan combined with fluid restriction to treat the syndrome of inappropriate antidiuresis: A case report

RATIONALE: Tolvaptan, an oral vasopressin V(2) receptor antagonist, is a new approach for the treatment of adult patients with the syndrome of inappropriate antidiuresis (SIADH). However, dose-dependent side effect including rapid increase in serum sodium levels and liver injury, and the expensive p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Xianxian, Pan, Hui, Zhu, Huijuan, Li, Jiapei, Miao, Hui, Ke, Xiaoan, Chen, Shi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
4300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824761/
https://www.ncbi.nlm.nih.gov/pubmed/31651865
http://dx.doi.org/10.1097/MD.0000000000017586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824761/
https://www.ncbi.nlm.nih.gov/pubmed/31651865
http://dx.doi.org/10.1097/MD.0000000000017586

Ejemplares similares